Kura Oncology, Inc.
22
9
9
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.2%
4 terminated/withdrawn out of 22 trials
55.6%
-30.9% vs industry average
5%
1 trials in Phase 3/4
100%
5 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Role: lead
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Role: collaborator
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Role: lead
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Role: lead
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Role: lead
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Role: collaborator
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Role: lead
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Role: lead
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Role: collaborator
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Role: collaborator
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Role: lead
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
Role: collaborator
Expanded Access to Ziftomenib
Role: lead
Expanded Access to Tipifarnib
Role: lead
Tipifarnib in Subjects With Myelodysplastic Syndromes
Role: lead
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
Role: lead
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Role: lead
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Role: lead
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
Role: lead
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Role: lead